Dan Yang1, Connor Galen O'Brien2, Gentaro Ikeda2, Jay H Traverse3, Doris A Taylor4, Timothy D Henry5, Roberto Bolli6, Phillip C Yang7. 1. State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Division of Cardiovascular Medicine, Department of Medicine, and Cardiovascular Institute, Stanford University School of Medicine, CA, USA. 2. Division of Cardiovascular Medicine, Department of Medicine, and Cardiovascular Institute, Stanford University School of Medicine, CA, USA. 3. Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA. 4. Regenerative Medicine Research, Texas Heart Institute, PO Box 20345, Houston, TX, USA. 5. The Carl and Edyth Lindner Center for Research and Education, The Christ Hospital Health Network, Cincinnati, OH, USA. 6. Institute of Molecular Cardiology, University of Louisville, KY, USA. 7. Division of Cardiovascular Medicine, Department of Medicine, and Cardiovascular Institute, Stanford University School of Medicine, CA, USA. Electronic address: phillip@stanford.edu.
Abstract
BACKGROUND: Mononuclear cells (MNCs) have been tested in clinical trials across multiple cardiovascular pathologies with mixed results. Major adverse cardiac events (MACE) and markers of cardiovascular capacity have been particularly challenging to interpret because of small size. This meta-analysis is aimed to assess the efficacy of MNC therapy in randomized clinical trials to identify the markers of efficiency that could influence future trial design. METHODS: PubMed, Embase, Cochrane library, and ClinicalTrials.gov were searched from inception through November 8, 2018. Changes in left ventricular ejection fraction (LVEF) and infarct size from baseline to follow-up were selected as primary outcomes. Changes in the left ventricular end-systolic volume, left ventricular end-diastolic volume, brain natriuretic peptide/N-terminal pro-B-type natriuretic peptide, 6-minute walk test, New York Heart Association class, and MACE incidences were considered secondary outcomes. RESULTS: In short-term follow-up, patients treated with MNCs demonstrated a significant increase in absolute LVEF of 2.21% (95% CI 1.59-2.83; P < .001; I2 = 32%) and 6.01% (95% CI 4.45-7.57; P < .001; I2 = 0%) in acute myocardial infarction (AMI) and ischemic cardiomyopathy studies, respectively. This effect was sustained in long-term follow-up. MNC therapy significantly reduced left ventricular end-systolic volume; however, infarct size, 6-minute walk test, New York Heart Association class, and MACE rates were comparable. CONCLUSIONS: MNC therapy may convey a modest but sustained increase in LVEF in ischemic cardiomyopathy patients, supporting further investigation. AMI trials, however, demonstrated minimal improvement in LVEF of unclear clinical significance, suggesting a limited role for MNC therapy in AMI.
BACKGROUND: Mononuclear cells (MNCs) have been tested in clinical trials across multiple cardiovascular pathologies with mixed results. Major adverse cardiac events (MACE) and markers of cardiovascular capacity have been particularly challenging to interpret because of small size. This meta-analysis is aimed to assess the efficacy of MNC therapy in randomized clinical trials to identify the markers of efficiency that could influence future trial design. METHODS: PubMed, Embase, Cochrane library, and ClinicalTrials.gov were searched from inception through November 8, 2018. Changes in left ventricular ejection fraction (LVEF) and infarct size from baseline to follow-up were selected as primary outcomes. Changes in the left ventricular end-systolic volume, left ventricular end-diastolic volume, brain natriuretic peptide/N-terminal pro-B-type natriuretic peptide, 6-minute walk test, New York Heart Association class, and MACE incidences were considered secondary outcomes. RESULTS: In short-term follow-up, patients treated with MNCs demonstrated a significant increase in absolute LVEF of 2.21% (95% CI 1.59-2.83; P < .001; I2 = 32%) and 6.01% (95% CI 4.45-7.57; P < .001; I2 = 0%) in acute myocardial infarction (AMI) and ischemic cardiomyopathy studies, respectively. This effect was sustained in long-term follow-up. MNC therapy significantly reduced left ventricular end-systolic volume; however, infarct size, 6-minute walk test, New York Heart Association class, and MACE rates were comparable. CONCLUSIONS:MNC therapy may convey a modest but sustained increase in LVEF in ischemic cardiomyopathypatients, supporting further investigation. AMI trials, however, demonstrated minimal improvement in LVEF of unclear clinical significance, suggesting a limited role for MNC therapy in AMI.
Authors: Tommi Pätilä; Miia Lehtinen; Antti Vento; Jukka Schildt; Juha Sinisalo; Mika Laine; Pekka Hämmäinen; Anne Nihtinen; Riitta Alitalo; Päivi Nikkinen; Aapo Ahonen; Miia Holmström; Kirsi Lauerma; Reino Pöyhiä; Markku Kupari; Esko Kankuri; Ari Harjula Journal: J Heart Lung Transplant Date: 2014-02-14 Impact factor: 10.247
Authors: Stefan Janssens; Christophe Dubois; Jan Bogaert; Koen Theunissen; Christophe Deroose; Walter Desmet; Maria Kalantzi; Lieven Herbots; Peter Sinnaeve; Joseph Dens; Johan Maertens; Frank Rademakers; Steven Dymarkowski; Olivier Gheysens; Johan Van Cleemput; Guy Bormans; Johan Nuyts; Ann Belmans; Luc Mortelmans; Marc Boogaerts; Frans Van de Werf Journal: Lancet Date: 2006-01-14 Impact factor: 79.321
Authors: J Alberto San Roman; Pedro L Sánchez; Adolfo Villa; Ricardo Sanz-Ruiz; María Eugenia Fernandez-Santos; Federico Gimeno; Benigno Ramos; Roman Arnold; Ana Serrador; Hipólito Gutiérrez; Francisco Martin-Herrero; María Jesús Rollán; Felipe Fernández-Vázquez; Juan López-Messa; Pablo Ancillo; German Pérez-Ojeda; Francisco Fernández-Avilés Journal: J Am Coll Cardiol Date: 2015-06-09 Impact factor: 24.094
Authors: Gabriel C Brooks; Byron K Lee; Rajni Rao; Feng Lin; Daniel P Morin; Steven L Zweibel; Alfred E Buxton; Mark J Pletcher; Eric Vittinghoff; Jeffrey E Olgin Journal: J Am Coll Cardiol Date: 2016-03-15 Impact factor: 24.094
Authors: Bodo E Strauer; Michael Brehm; Tobias Zeus; Matthias Köstering; Anna Hernandez; Rüdiger V Sorg; Gesine Kögler; Peter Wernet Journal: Circulation Date: 2002-10-08 Impact factor: 29.690
Authors: José C Nicolau; Remo H M Furtado; Suzana A Silva; Carlos E Rochitte; Anis Rassi; João B M C Moraes; Edgard Quintella; Costantino R Costantini; Adrian P M Korman; Marco A Mattos; Hélio J Castello; Adriano Caixeta; Hans F R Dohmann; Antonio C C de Carvalho Journal: Clin Cardiol Date: 2018-03-22 Impact factor: 2.882
Authors: Jay H Traverse; David H McKenna; Karen Harvey; Beth C Jorgenso; Rachel E Olson; Nancy Bostrom; Diane Kadidlo; John R Lesser; Vikrant Jagadeesan; Ross Garberich; Timothy D Henry Journal: Am Heart J Date: 2010-09 Impact factor: 4.749